CYP2C19 in ACS Patients: Could Genotyping Have a Role in Medically Managed Patients or Beyond?

In this respect, the TRILOGY-ACS genetic substudy (4) included only a few patients with poor metabolizer status, and the authors did not report specifically on the outcome of clopidogrel-treated poor metabolizers. [...]investigations are needed here before definite conclusions can be drawn. [...]the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2016-03, Vol.67 (8), p.948-950
Hauptverfasser:	Sibbing, Dirk, Gross, Lisa, Massberg, Steffen
Format:	Artikel
Sprache:	eng
Schlagworte:	acute coronary syndrome Acute Coronary Syndrome - drug therapy Acute coronary syndromes Angina pectoris Cardiology Confidence intervals Cytochrome P-450 CYP2C19 - genetics DNA - genetics Drug dosages dual antiplatelet therapy Female genetics Genotype & phenotype Heart attacks Humans Male platelets Polymorphism, Genetic Prasugrel Hydrochloride - administration & dosage Studies Thrombosis Ticlopidine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this respect, the TRILOGY-ACS genetic substudy (4) included only a few patients with poor metabolizer status, and the authors did not report specifically on the outcome of clopidogrel-treated poor metabolizers. [...]investigations are needed here before definite conclusions can be drawn. [...]the present results are limited by the circumstance that the authors report ischemic outcomes only.
ISSN:	0735-1097 1558-3597
DOI:	10.1016/j.jacc.2016.01.002